Breaking Research
Apr 27
2023
Drug’s development stemmed from collaborative research from Packard Center investigators.
Feb 3
2022
A Pathway to Discovery and Hope for ALS Patients and Researchers: A massive biological genetic and clinical resource for ALS and neurodegenerative diseases.
Jul 28
2021
Packard researchers used Answer ALS cell lines to show that the protein CHMP7 accumulates in the nucleus, triggering a series of events that creates some of the molecular hallmarks found in both sporadic and familial ALS as well as FTD.
Jan 8
2021
The Answer ALS data portal seeks to empower researchers around the globe with the data needed to finally answer ALS.
To see the video tribute
May 11
2017
The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease
Rea entire press release on www.fda.gov
Nov 5
2015
Molecular differences between C9orf72 mutation-associated and sporadic ALS
